戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ultielectrode mapping catheters in recording diastolic activity may help predict those VTs employing
2 ad full diastolic activity recorded, partial diastolic activity recorded, or underwent substrate modi
3 s 88%, 50%, and 55% in patients who had full diastolic activity recorded, partial diastolic activity
4    The primary endpoint was change in LV end-diastolic and -systolic volume assessed by cardiac magne
5  was no difference in change in LVEF, LV end diastolic and end systolic diameters between the 2 group
6                              At baseline HR, diastolic and mean arterial pressures in IST and POTS we
7 +)](Nuc) was similar to [Ca(2+)](Cyto); both diastolic and resting [Ca(2+)](Nuc) increased with AF.
8 holds for abnormal myocardial relaxation and diastolic and systolic dysfunction (LV ejection fraction
9 njury, pathological cardiac remodelling, and diastolic and systolic dysfunction.
10  We examined associations between SDB and LV diastolic and systolic function using data from 1506 adu
11 ated glomerular filtration rate (eGFR), CFR, diastolic and systolic indices, and adverse cardiovascul
12            eGFR and CFR were associated with diastolic and systolic indices, as well as future cardio
13 antify relative wall thickness, LV mass, and diastolic and systolic LV function; and a standardized n
14 stations in PEX, involving signs of abnormal diastolic and systolic right ventricular function and co
15 res ANOVA were used to observe the systolic, diastolic, and mean arterial pressure (MAP) correlations
16       Changes in femoral dP/dtmax, systolic, diastolic, and pulse femoral arterial pressure were obta
17  the 600-IU group, central-systolic, central-diastolic, and systemic-diastolic BP was lower at 6 mo i
18  mitral peak early filling velocity-to-early diastolic annular velocity ratio decreased (absolute dec
19 olic transmitral flow velocity to peak early-diastolic annular velocity ratio, E/E': sham, 13.6+/-2.1
20 imaging markers have future potential for RV diastolic assessment.
21 esulted in clinically relevant reductions in diastolic blood pressure (- 3.1 mmHg [- 5.8, - 0.3]).
22 ted OR, 2.41; P=0.01) and increased baseline diastolic blood pressure (adjusted OR, 1.23 per 10-point
23  was negatively associated with systolic and diastolic blood pressure (beta = -0.194; 95% CI: -0.153,
24 ight, waist circumference (WC), systolic and diastolic blood pressure (BP), fasting blood glucose, gl
25 primary outcomes were change in systolic and diastolic blood pressure (BP), Short Physical Performanc
26 9:00 and 22:00 had the greatest reduction in diastolic blood pressure (DBP) (P = 0.02) but also the m
27           The systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressur
28               The prognostic significance of diastolic blood pressure (DBP) and resting heart rate (R
29 T on endothelial function and systolic (SBP)/diastolic blood pressure (DBP) in individuals with prehy
30 of dietary patterns on systolic (SBP) and/or diastolic blood pressure (DBP) levels.
31 r, observational data suggest that excessive diastolic blood pressure (DBP) lowering might increase t
32 in systolic blood pressure (SBP) or >= 10 in diastolic blood pressure (DBP) upon standing classified
33 elated with fasting blood glucose, HbA1c and diastolic blood pressure (DBP), and positively correlate
34 llected in mid-adulthood: systolic (SBP) and diastolic blood pressure (DBP), high-density-lipoprotein
35 trate that a genetic increase of 10 mm Hg in diastolic blood pressure (odds ratio, 1.43 [95% CI, 1.24
36               With the exception of IL16 and diastolic blood pressure (P=0.58), these relationships w
37 nary resuscitation, these patients had lower diastolic blood pressure (point estimate, -6.68 mm Hg [-
38 vascular conductance (FVC; regional sNVT) or diastolic blood pressure (systemic sNVT).
39 systolic blood pressure [SBP] >=140 mm Hg or diastolic blood pressure [DBP] >=90 mm Hg) and normal (S
40 ) offspring had 1-2 mmHg higher systolic and diastolic blood pressure across the life course, but low
41 etes), disease risk factors (e.g., increased diastolic blood pressure and body mass index), and poore
42                                              Diastolic blood pressure and pulse pressure are causally
43 tress and steepened the relationship between diastolic blood pressure and sympathetic discharge frequ
44 retic peptide), systolic blood pressure, and diastolic blood pressure confirmed previous reports.
45 is assessed reductions in systolic (SBP) and diastolic blood pressure from pharmacological treatments
46 lood pressure among men aged <=67 years with diastolic blood pressure greater than 80 mm Hg to 1.00 (
47  TRE may significantly decrease systolic and diastolic blood pressure independent of weight loss.
48 (systolic blood pressure level >140 mm Hg or diastolic blood pressure level >90 mm Hg), uncontrolled
49                        The mean reduction in diastolic blood pressure was 2.8 mm Hg greater in the in
50 d pressure was 154 (14.9) mm Hg and the mean diastolic blood pressure was 83.3 (9.9) mm Hg.
51                                     Systemic diastolic blood pressure was reduced (0 W, 40%; P < 0.05
52 inute and the mean decreases in systolic and diastolic blood pressure were 7.1+/-18.8mmHg and 5.3+/-9
53              PRS for increased education and diastolic blood pressure were associated with reduced ri
54 ood pressure, 2.4% (95% CI: 0.6, 4.3) higher diastolic blood pressure, 2.1% (95% CI: 0.5, 3.8) higher
55 to body mass index, systolic blood pressure, diastolic blood pressure, and pulse pressure in the UK B
56 MI, waist and hip measurements, systolic and diastolic blood pressure, and triglycerides were higher
57 ge, height, weight, systolic blood pressure, diastolic blood pressure, current smoking, antihypertens
58 were positively associated with systolic and diastolic blood pressure, faecal SCFAs, Bacteroides pleb
59 t, current smoking, systolic blood pressure, diastolic blood pressure, hypertension treatment, diabet
60 cular risk profile of increased systolic and diastolic blood pressure, increased C-reactive protein (
61  arterial pressure [systolic blood pressure, diastolic blood pressure, mean arterial pressure (MAP)],
62  genetic effects on systolic blood pressure, diastolic blood pressure, mean arterial pressure, and pu
63 nt differences in improvement in systolic or diastolic blood pressure, nonvertebral fractures, physic
64 ry of hypertension, systolic blood pressure, diastolic blood pressure, tobacco use, statin use, body
65 fection with lower triglycerides, LDL-c, and diastolic blood pressure.
66 ic and 0.76 mm Hg (95% CI (-1.39, -0.13)) in diastolic blood pressure.
67 pressure; IL (interleukin) 16 was related to diastolic blood pressure; cFn (cellular fibronectin) and
68                         Central systolic and diastolic blood pressures increased more quickly during
69                                 Systolic and diastolic blood pressures provide information about card
70 K women without PCOS had higher systolic and diastolic blood pressures, and increased testosterone re
71  smoking, duration of diabetes, systolic and diastolic blood pressures, pulse, low-density lipoprotei
72 n had a higher body mass index, systolic and diastolic blood pressures, triglycerides (p < 0.01), whi
73 DH, by 2017 ACC/AHA (systolic BP <130 mm Hg, diastolic BP >=80 mm Hg) and by JNC7 (systolic BP <140 m
74  mm Hg) and by JNC7 (systolic BP <140 mm Hg, diastolic BP >=90 mm Hg) definitions.
75 to -3.0; P < 0.001) and a greater decline in diastolic BP (-2.1 mm Hg, 95% CI -3.6 to -0.6; P < 0.006
76 hip of lymphocyte count with systolic BP and diastolic BP (causal estimates: 0.69 [95% CI, 0.19-1.20]
77 ship exists between systolic BP (SBP) and/or diastolic BP (DBP) and risk of Alzheimer's disease (AD).
78 ential visits for both systolic BP (SBP) and diastolic BP (DBP), and further assessed the direction o
79 sitive genetic correlations of migraine with diastolic BP (DBP, r(g) = 0.11, P = 3.56 x 10(-06)) and
80 .34), which was also the case for ambulatory diastolic BP (P = 0.45).
81  both systolic (R(2) = 0.1384, P = 0.01) and diastolic BP (R(2) = 0.2437, P = 0.0008); (3) BFM was po
82 tolic BP (SD -0.11; 95% CI -0.19, -0.02) and diastolic BP (SD -0.11; 95% CI -0.19, -0.04).
83 r more in systolic BP or 10 mm Hg or more in diastolic BP after changing position from seated to stan
84 c BP fell by 6.55 mm Hg (SD 15.17), and mean diastolic BP by 4.23 mm Hg (SD 8.68).
85 s systolic BP level lower than 140 mm Hg and diastolic BP level lower than 90 mm Hg.
86 as systolic BP level of 140 mm Hg or higher, diastolic BP level of 90 mm Hg or higher, or use of anti
87 -0.18, P value = 4.72 x 10-3), and automated diastolic BP measurement (beta 0.09, 95% CI, 0.03-0.16,
88 ble inverse effects of elevated systolic and diastolic BP on large artery stroke.
89  Mean arterial pressure (MAP) was defined as diastolic BP plus 1/3 (systolic BP - diastolic BP).
90                                      The new diastolic BP threshold of 80 mm Hg was recommended based
91 bal domains (P=0.010), and higher cumulative diastolic BP was associated with lower cognitive perform
92 al-systolic, central-diastolic, and systemic-diastolic BP was lower at 6 mo in the 1000-IU group [-2.
93 justment for covariates, clinic systolic and diastolic BP were strongly associated with cardiovascula
94 spectively; the difference in mean change in diastolic BP with omega-3s vs no omega-3s was -0.5 (99%
95 ined as diastolic BP plus 1/3 (systolic BP - diastolic BP).
96 eutrophil counts, and increased systolic BP, diastolic BP, and pulse pressure was observed (eg, adjus
97     Analyses were performed for systolic BP, diastolic BP, mean arterial pressure, and pulse pressure
98 for systolic and 0.918, 0.847, and 0.843 for diastolic BP, respectively.
99 hip of lymphocyte count with systolic BP and diastolic BP.
100               Higher cumulative systolic and diastolic BPs were associated with slower walking speed
101                ISO also produced spontaneous diastolic Ca(2+) elevation in DBH-Sap but not control he
102             In a failing heart, the elevated diastolic Ca(2+) leak from the sarcoplasmic reticulum ca
103  of the channel, resulting in a pathological diastolic Ca(2+) leak from the SR that both triggers arr
104  AF-induced IP(3)R1 upregulation and nuclear diastolic Ca(2+)-loading.
105                                              Diastolic [Ca(2+)](Nuc) was greater than [Ca(2+)](Cyto)
106 TP that causes elevated cytoplasmic resting (diastolic) Ca(2+) concentration and reduced mechanical p
107  time of the calcium transient and increased diastolic calcium levels.
108  as well as its contribution to systolic and diastolic cardiac dysfunction and impaired clinical outc
109   Only 2.1% of the stacks had an average end-diastolic cardiac image contrast below 30% of the dynami
110 imination task synchronized with systolic or diastolic cardiac phase.
111 high trust faces specifically during relaxed diastolic cardiac states.
112              Training decreased systolic and diastolic central (aortic) blood pressure by 4 mm Hg (95
113 ongitudinal systolic strain rate), and early diastolic conduit (LA longitudinal early diastolic strai
114 s including calculation of peak systolic and diastolic control-averaged left ventricular (LV) velocit
115                      It caused inhibition at diastolic cytoplasmic [Ca(2+)] but not at Ca(2+) levels
116                  Our simulations reveal that diastolic cytosolic Ca(2+) elevation as a result of rapi
117 ulum Ca(2+) release, which, in turn, reduces diastolic cytosolic Ca(2+), leading to alternations in d
118 cytosolic Ca(2+), leading to alternations in diastolic cytosolic Ca(2+), RyR2 inactivation, and sarco
119 city (PWV), together with systolic (SBP) and diastolic (DBP) blood pressure.
120 n (12 patients), followed by LV systolic and diastolic deterioration (in 5 patients).
121 cular ejection fraction was 14.5+/-5.3%, end-diastolic diameter was 7.33+/-0.89 cm, end-systolic diam
122  ventricular ejection fraction, 57+/-8%; end-diastolic diameter, 4.81+/-0.58 cm; end-systolic diamete
123 s the composite of left ventricular (LV) end-diastolic dimension <33 mm/m(2) and absolute increase in
124                         Left ventricular end-diastolic dimension and mitral peak early filling veloci
125 inent in patients whose left ventricular end-diastolic dimension Z score before intervention is >2, i
126 atients with a baseline left ventricular end-diastolic dimension Z score of >2 exhibited a significan
127 observed in 39% of patients), followed by LV diastolic dysfunction (16%) and LV systolic dysfunction
128 hors aimed to assess the association between diastolic dysfunction (DD) and outcomes in patients with
129 f both sexes developed left ventricular (LV) diastolic dysfunction (DD), with 25% exhibiting grade II
130 t banding induced concentric hypertrophy and diastolic dysfunction (early diastolic transmitral flow
131 he relationship between these indices and LV diastolic dysfunction and exertional symptoms has not be
132 essure overload and subsequently leads to LV diastolic dysfunction and heart failure over time.
133 pertension-induced cardiac injury, including diastolic dysfunction and impaired calcium handling.
134 ntified subclinical disease features such as diastolic dysfunction and late gadolinium enhancement.
135 very of systolic function but persistence of diastolic dysfunction and no coronary aneurysms.
136 herapies similarly improved left ventricular diastolic dysfunction and reduced left atrial diameter.
137 d 1.07-fold (1.03-1.11) higher prevalence of diastolic dysfunction as well as 1.3 (0.3-2.4) g/m(2) gr
138 ure; however, clinical tools for identifying diastolic dysfunction before echocardiography remain imp
139 ft ventricular dysfunction, left ventricular diastolic dysfunction grade II or III, right ventricular
140 s with concentric LV remodeling and isolated diastolic dysfunction had the poorest cognitive function
141 anding, 1.96x10(8)+/-6.8x10(7), P<0.001) and diastolic dysfunction improved simultaneously (E/E': ban
142 2% of participants and left ventricular (LV) diastolic dysfunction in 88%.
143 l myocardial fibrosis and is associated with diastolic dysfunction in sickle cell anemia (SCA).
144                                              Diastolic dysfunction is a prevalent and therapeutically
145                                              Diastolic dysfunction is a prominent feature of cardiac
146                                              Diastolic dysfunction is associated with a high risk for
147                        Left ventricular (LV) diastolic dysfunction is recognized as playing a major r
148 ne the effect of chronic PDE9a inhibition, 2 diastolic dysfunction mouse models were studied: (1) TAC
149 rmal (median from 54% to 64%; p < 0.001) but diastolic dysfunction persisted.
150              ADHF was defined as systolic or diastolic dysfunction requiring continuous vasoactive or
151  energetics, left ventricle hypertrophy, and diastolic dysfunction to recover.
152                                        As LV diastolic dysfunction typically precede heart failure sy
153 rmal predicted left atrial pressure (grade I diastolic dysfunction) had a measured pulmonary artery o
154 sed left ventricular remodeling (hypertrophy/diastolic dysfunction), age, injury (high-sensitivity tr
155 predicted left atrial pressure (grade II/III diastolic dysfunction), only 17 (71%) had a pulmonary ar
156          Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor.
157 was related to LV concentric remodelling and diastolic dysfunction, and associated with poorer clinic
158  with concentric remodelling and more severe diastolic dysfunction, especially in LF AS.
159 c cardiomyopathy are cardiac hypertrophy and diastolic dysfunction, which lead to heart failure, espe
160 re growth restricted and showed systolic and diastolic dysfunction, with an increase in cardiomyocyte
161 ssociated with echocardiographic evidence of diastolic dysfunction.
162 ejection fraction (EF) group in MIS-C showed diastolic dysfunction.
163 ar function accompanied by both systolic and diastolic dysfunction.
164 e (BNP), and echocardiographic parameters of diastolic dysfunction.
165 ables as a first step in the detection of LV diastolic dysfunction.
166 apeutic applications in cardiac fibrosis and diastolic dysfunction.
167 f detyrosination as a therapeutic target for diastolic dysfunction.
168 d that inhibiting PDE9a activity ameliorates diastolic dysfunction.
169 LV hypertrophy and subclinical markers of LV diastolic dysfunction.
170 n, increases calcium sensitivity, and causes diastolic dysfunction.
171                  The duration of the longest diastolic electrogram was inversely correlated with the
172 nce, but the viscoelastic forces that resist diastolic filling and become elevated in human HF are po
173 d augmentation in lusitropy, indicating that diastolic filling of the right heart is not passive.
174  indexes with right ventricular systolic and diastolic findings (P < .05 for all).
175 ntile < 3rd/< 10th with absent umbilical end-diastolic flow, < 34 weeks).
176 relation between indices of COA severity, LV diastolic function (average e' and E/e'), and exertional
177 /- 0.06 vs 0.29 +/- 0.04; P = .002), reduced diastolic function (diastolic strain rate, 1.10 +/- 0.23
178 ibrosis (r = 0.48; P = .04) and inversely to diastolic function (r = -0.49; P = .03).
179 se mitochondrial reversible changes underlie diastolic function adaptations during myocardial (revers
180 or ICAM-1 was associated with measures of LV diastolic function after multivariable adjustment.
181  ratio had the strongest correlation with LV diastolic function and exertional symptoms.
182 s in left ventricular ejection fraction, the diastolic function and longitudinal strain improved.
183 reserved in the majority of patients, but LV diastolic function and RV function are impaired.
184 n between the indices of COA severity and LV diastolic function and symptoms.
185  included left ventricular (LV) systolic and diastolic function and valve hemodynamics and right vent
186            Whereas myocardial energetics and diastolic function are impaired in obesity, systolic fun
187                Few studies have evaluated if diastolic function could predict outcomes in patients wi
188                                              Diastolic function declined during follow-up in particip
189                                              Diastolic function grading might improve risk stratifica
190 vitro and in vivo, leading to improvement in diastolic function in 2 hypertension-dependent rodent mo
191 ified evidence of abnormal right ventricular diastolic function in 29% of patients with PEX and ident
192         Assessment of right ventricular (RV) diastolic function is not routinely carried out.
193                             Exact grading of diastolic function might improve risk stratification for
194                                     Improved diastolic function was concordant with increased phospho
195                                       Normal diastolic function was found in 23 (11%) patients, dysfu
196                                              Diastolic function was graded normal (N) or dysfunction
197 nd diabetes, the improvement in systolic and diastolic function was not secondary to a reduction in l
198 al energetics, myocardial lipid content, and diastolic function were also demonstrated in the wider s
199 underwent assessment of cardiac systolic and diastolic function, myocardial energetics ((31)P-magneti
200 d a median of 2.1 years later to quantify LV diastolic function, systolic function, and structure.
201 ed a significant improvement in systolic and diastolic functions with boron treatment compared to sal
202  diastolic <90); and high (systolic >=140 or diastolic &gt;=90).
203 ith OBP (3 visits) or 24-h ABP, systolic and diastolic HBP (1 week) were more reliable and more stron
204 P and 24-h ABP, 10 mm Hg higher systolic and diastolic HBP were associated with 5.07 (standard error
205 ure >=130 mmHg for systolic or >=85 mmHg for diastolic, HDL cholesterol <40 mg/dL for males and <50 m
206 d stiffness contribute to the development of diastolic heart failure in other settings.
207 nd who underwent cardiac transplantation for diastolic heart failure, her father with left ventricula
208 e involvement of the heart, characterized by diastolic heart failure, the presence of amyloid deposit
209 inion and changes the definition of isolated diastolic hypertension (IDH).
210 l oxygen consumption and induce arrhythmias, diastolic hypotension may reduce coronary perfusion and
211 d clinically for treatment of epilepsy, is a diastolic inhibitor of cardiac calcium release channels
212 he evidence of having had recorded the whole diastolic interval.
213 en considers how the control of systolic and diastolic intracellular Ca(2+) concentration is intimate
214          Little, however, is known about how diastolic intracellular Ca(2+) concentration is regulate
215  reviewing the basic mechanisms that control diastolic intracellular Ca(2+) concentration.
216 rams were used to measure cardiac mechanics: diastolic (lateral and septal E/e') and systolic (global
217 idge cycling is defectively suppressed under diastolic/low Ca(2+) conditions in the presence of HCM/R
218 systolic <100); normal (systolic 100-139 and diastolic &lt;90); and high (systolic >=140 or diastolic >=
219 tween early mitral inflow velocity and early diastolic mitral annular velocity (E/e') was associated
220  analysis allows comprehensive assessment of diastolic myocardial function, which is not indicated by
221 fter adjustment for HBP, neither systolic or diastolic OBP nor ABP was associated with LVMI.
222  33 +/- 17 bursts.100 Hb(-1) ; P = 0.01) and diastolic operating pressure (82 +/- 8 to 80 +/- 8 mmHg;
223                 There were no differences in diastolic or systolic blood pressures or event survival
224                             Left ventricular diastolic or systolic dysfunction results in increased p
225     We aimed to explore the role of complete diastolic pathway activation mapping on VT recurrence.
226 ic pathway, partial diastolic pathway, or no diastolic pathway map performed.
227                         However, the role of diastolic pathway mapping on VT recurrence has yet to be
228                     Partial recording of the diastolic pathway of the clinical VT was achieved in 24/
229                          No recording of the diastolic pathway of the clinical VT was feasible in 25/
230  from VT recurrence as compared with partial diastolic pathway recording and substrate modification.
231                                         Full diastolic pathway recording has been associated with a h
232                    Complete recording of the diastolic pathway was achieved in 36/85 (42.4%) patients
233                        Mapping of the entire diastolic pathway was associated with a higher freedom f
234 recorded the full diastolic pathway, partial diastolic pathway, or no diastolic pathway map performed
235 were categorized as having recorded the full diastolic pathway, partial diastolic pathway, or no dias
236 ncreasing ventricular compliance can improve diastolic performance, but the viscoelastic forces that
237 eflecting poor left ventricular systolic and diastolic performance, is associated with increased shor
238 (2+) and APs allowed measurements of maximum diastolic potential and AP duration during triggered cal
239 d NCX and dramatically reduce atrial maximum diastolic potential and prolong AP duration, establishin
240                                      Maximum diastolic potential was reduced, and AP duration was sig
241 RV dysfunction was indicated by elevated end-diastolic pressure (11.3+/-2.5 versus 5.7+/-2.0 mm Hg; P
242 temperature (P = .31), heart rate (P = .92), diastolic pressure (P = .31), or systolic pressure (P =
243 gement (p < 0.0001) and marginally increased diastolic pressure (p = 0.09).
244 gridAND correlated with left ventricular end-diastolic pressure across both groups (average R(2) = 0.
245 , mean arterial pressure, systolic pressure, diastolic pressure, and left ventricular systolic pressu
246 ant change in heart rate or left ventricular diastolic pressure.
247 ilable arm cuff device yielding systolic and diastolic readings ((mean+/-SD) mmHg) of (-0.9 +/- 7.3)
248 ative intensity indicating ventricular early diastolic relaxation also did not change.
249                                     Impaired diastolic relaxation and preserved ejection fraction wer
250 n-measurable quantities; namely, ventricular diastolic relaxation, systemic resistance, pulmonary ven
251                                              Diastolic secondary eigenvector angle was correlated wit
252                                       In CA, diastolic secondary eigenvector angle was elevated, and
253 four LV anatomic structures performed on end-diastolic short-axis cine cardiac MRI: LV trabeculations
254 been associated with increased cardiomyocyte diastolic stiffness in heart failure with preserved ejec
255 usefulness of PDE9a inhibition to treat high-diastolic stiffness may be limited as the required PDE9a
256 tolic strain rate, and LA longitudinal early diastolic strain rate values were 12.9+/-4.8%, 0.80+/-0.
257 rly diastolic conduit (LA longitudinal early diastolic strain rate) phases were analyzed using 2-dime
258 0.04; P = .002), reduced diastolic function (diastolic strain rate, 1.10 +/- 0.23 s-1 vs 1.39 +/- 0.2
259 tolic strain rate, and LA longitudinal early diastolic strain rate, respectively; all P<0.001).
260                 Circumferential systolic and diastolic strain rates displayed moderate correlation to
261 n reduced myocyte stiffness, particularly at diastolic strain rates, indicating reduced viscous force
262 nge, wherein cyclic deformation of TT during diastolic stretch and systolic shortening serves to mix
263 ribute meaningful viscoelastic resistance to diastolic stretch in human myocardium.
264 rosination lowers viscoelastic resistance to diastolic stretch in human myocytes and myocardium.
265         Viscoelasticity was increased during diastolic stretch of HF cardiomyocytes compared with non
266   Microtubule (MT) mechanotransduction links diastolic stretch to generation of NADPH oxidase 2 (NOX2
267 rotubule mechanotransduction pathway linking diastolic stretch to NADPH oxidase 2-derived reactive ox
268 ule network provides a viscous impediment to diastolic stretch, particularly in HF.
269                       First, slow and rapid (diastolic) stretch was applied to intact cardiomyocytes
270                            Segments with end diastolic thickness >= 1.2 cm had a higher burden of LGE
271 hypertrophy and diastolic dysfunction (early diastolic transmitral flow velocity to peak early-diasto
272           In the atrial systolic phase, peak diastolic velocity in the LV correlated with septal thic
273 luid loading increased right ventricular end-diastolic volume (+31 +/- 13 mL; p = 0.004), right ventr
274 s of end-systolic volume (0 +/- 3.3 ml), end-diastolic volume (- 0.4 +/- 2.0 ml) and ejection fractio
275 iated with a significant reduction of LV end-diastolic volume (-25.1 +/- 26.0 ml vs. -1.5 +/- 25.4 ml
276 ic treatment decreased right ventricular end-diastolic volume (-84 +/- 11 mL; p < 0.001), right ventr
277 l was causally associated with higher LV end-diastolic volume (beta = 1.85 ml; 95% confidence interva
278 olume (ESV: Pearson r = 0.99, P < .001), end-diastolic volume (EDV: r = 0.97, P < .001), and ejection
279 were obtained with MRI: Left ventricular end-diastolic volume (LVDV) was 40 mL (LVDV per body surface
280 ff values for change in left ventricular end-diastolic volume (LVEDV) and LV end-systolic volume (LVE
281 mong patients with available baseline LV end-diastolic volume (LVEDV) measures, 188 received biventri
282 rformance according to the median PET LV end-diastolic volume (LVEDV), with smaller LVs defined as ha
283 ted QRS area for heart size using the LV end-diastolic volume (QRSarea/LVEDV).
284 ) nor PR volume (PRV) correlated with RV end-diastolic volume (r = 0.36; p = 0.15 and r = 0.37; p = 0
285                        Right ventricular end-diastolic volume (RVDV) was 262 mL (RVDV/BSA, 164 mL/m(2
286 eased LV weight/body weight ratio and LV end diastolic volume (WT, 50.8 mul; CatA-TG, 61.9 mul).
287      Patients with transplants had lower end-diastolic volume index (59.3+/-15.2 ml/m(2) vs. 71.4+/-1
288                          The left atrial end-diastolic volume index (LAEDVI), representing the minimu
289 between groups in baseline values for LV end-diastolic volume index and LV end-systolic volume index
290                 Empagliflozin reduced LV end-diastolic volume index by 8.2 (95% CI, -13.7 to -2.6) mL
291  threshold of 227% or a left ventricular end-diastolic volume index of 58 ml/m(2) identified patients
292 improvements in LV ejection fraction, LV end-diastolic volume index, and LV end-systolic volume index
293 vascular magnetic resonance measures (LV end-diastolic volume index, LV ejection fraction), diuretic
294 ft atrial volume index, left ventricular end-diastolic volume index, peak E wave, and the presence of
295 ejection fraction (LVEF) and left atrial end-diastolic volume indexed to body surface area, were asse
296           Automatic quantification of LV end-diastolic volume, LV myocardium mass, LV trabeculation,
297 sed significantly during exercise, while end-diastolic volumes were essentially unchanged.
298 tion to peak systolic (r=-0.38, p=0.022) and diastolic vorticity (r=0.40, p=0.015) values, respective
299 .014 +/- 0.007 rad-m(2)/ml-s; p=0.007), peak diastolic vorticity index (male: 0.007 +/- 0.006 rad-m(2
300                          As a result, LV end-diastolic wall thickness-to-chamber radius (h/R) ratio i

 
Page Top